Drug intelligence / Profile preview

capecitabine + ivermectin

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of two drugs, capecitabine and ivermectin. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), used as an antineoplastic agent for the treatment of various cancers, including colorectal, breast, gastric, esophageal, and pancreatic cancer[8][10]. Ivermectin is a macrocyclic lactone with antiparasitic activity and has also been investigated for antiviral and anti-inflammatory effects[2][7]. There is no widely recognized or approved use for this specific combination in clinical practice. The combination "capecitabine + ivermectin" does not appear in major drug databases or clinical guidelines as a standard therapy.

Other names: CAPA + ivermectin

Targets

TS (Thymidylate synthase)

Beyond the preview

Go deeper on capecitabine + ivermectin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on capecitabine + ivermectin.

Explore the full profile